June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Evaluation of LOXL-1 as a potential diagnostic and therapeutic target in exfoliation glaucoma
Author Affiliations & Notes
  • Andras Varadi
    Department of Ophthalmology, Columbia University, New York, New York, United States
  • Konstantin Petrukhin
    Department of Ophthalmology, Columbia University, New York, New York, United States
  • Footnotes
    Commercial Relationships   Andras Varadi, None; Konstantin Petrukhin, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4602. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Andras Varadi, Konstantin Petrukhin; Evaluation of LOXL-1 as a potential diagnostic and therapeutic target in exfoliation glaucoma. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4602.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Exfoliation glaucoma (XFG) is a common form of secondary glaucoma caused by progressive accumulation of insoluble elastic fiber-based microfibrillar deposits in the eye. XFG is the ocular manifestation of the age-related systemic disorder known as pseudoexfoliative syndrome (PEX); fibrillar deposits are found in various organs of PEX patients including the skin, heart, lungs, and brain. The disease is highly prevalent in the elderly in certain ethnic groups, suggesting the role of genetic and environmental factors. Its exact pathogenesis is not known, however, multiple single nucleotide polymorphisms in the lysyl oxidase-like 1 (LOXL-1) gene have been identified to correlate with PEX. LOXL-1 belongs to the family of amine oxidases responsible for the maintenance and crosslinking of elastin and collagen fibers. LOXL-1 is a component of pseudoexfoliative material and its expression is upregulated in the early stages of the disease, therefore, targeting LOXL-1 may be a viable strategy to treat XFG.

Methods : In order to develop assays that could serve as tools for the diagnosis of XFG from human samples based on LOXL-1 activity and to evaluate the enzyme as a potential drug target, we expressed and purified human LOXL-1 from E. coli constructs. Enzyme activity was measured using colorimetry, fluorimetry, and luminometry, leveraging the enzyme’s ability to generate aldehydes and hydrogen peroxide. Small molecules were screened using differential scanning fluorimetry for possible interaction with LOXL-1.

Results : A chemiluminescence-based assay method was developed that can be used to quantify lysyl oxidase activity in biological samples. Using differential scanning fluorimetry, we identified small molecules that affect the stability of LOXL-1 and screened these for enzyme inhibition.

Conclusions : Our results highlight LOXL-1 as a potential target for identifying and treating XFG.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×